Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Meera Mohan, Jorge Monge, Nishi Shah...
https://pubmed.ncbi.nlm.nih.gov/38443345/Actively Recruiting
Led by CHU de Quebec-Universite Laval · Updated on 2026-07-22
80
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are investigating the use of bispecific antibody therapies that target BCMA B-cell maturation antigen for patients with multiple myeloma, a serious blood cancer. These therapies are currently used mainly for patients with refractory multiple myeloma but are also being tested earlier in treatment. Because these treatments can cause deeper immunosuppression, patients face a higher risk of infections, making infection prevention a key concern. However, the best strategies for preventing infections in this group are not yet clear. The study compares two approaches to giving immunoglobulin Ig support to patients receiving BCMA-directed T-cell engager therapy. Patients with relapsed or refractory multiple myeloma who have a history of recurrent or severe infections or low IgG levels will receive Ig support either intravenously or subcutaneously. The study aims to determine if targeting a lower trough IgG level of 4 to 6 gL is as effective at reducing severe infections as the standard target level of 8 to 10 gL. Some patients without infection history or low IgG may not initially receive Ig support but may switch groups if needed during follow-up. Participants will be closely monitored for infections and IgG levels from enrollment through 12 months after randomization. The main measurement is the rate of severe infections within the first 3 months. Researchers will also track minor and all infections over a year. Regular assessments will include blood tests to measure IgG levels and infection evaluations. This randomized, unblinded study aims to provide guidance on optimal IgG targets to better protect multiple myeloma patients receiving these novel therapies. The trial runs from early 2026 through late 2029.
CONDITIONS
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
P
Philippe Nadeau, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CHU de Quebec-Universite Laval
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants receive immunoglobulin support aimed at different target IgG levels or may not receive immunoglobulin initially depending on infection history and IgG levels. Some may switch groups during follow-up if needed.
Regular visits for monitoring IgG levels and infections
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Meera Mohan, Jorge Monge, Nishi Shah...
https://pubmed.ncbi.nlm.nih.gov/38443345/Ann Gardulf, Uwe Nicolay, Dipl Math...
https://pubmed.ncbi.nlm.nih.gov/15480339/Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf...
https://pubmed.ncbi.nlm.nih.gov/37582952/Yi Guo, Xin Tian, Xuefeng Wang...
https://pubmed.ncbi.nlm.nih.gov/29951056/Kristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos...
https://pubmed.ncbi.nlm.nih.gov/38052042/Jian Lynn Lee, Noraida Mohamed Shah, Mohd Makmor-Bakry...
https://pubmed.ncbi.nlm.nih.gov/32417999/Noopur Raje, Kenneth Anderson, Hermann Einsele...
https://pubmed.ncbi.nlm.nih.gov/37528088/Thierry Ducruet, Marie-Claude Levasseur, Anne Des Roches...
https://pubmed.ncbi.nlm.nih.gov/23040368/Iris M Otani, Heather K Lehman, Artemio M Jongco...
https://pubmed.ncbi.nlm.nih.gov/35176351/Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk...
https://pubmed.ncbi.nlm.nih.gov/35661166/CHU de Quebec-Universite Laval
Lead Sponsor